Expert Review of Clinical Immunology最新文献_第7页

Treatment intensification in Kawasaki disease - current perspectives. 川崎病的强化治疗--当前视角。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-07-15 DOI: 10.1080/1744666X.2024.2378900

Prabal Barman, Rakesh Kumar Pilania, Gayathri Cv, Abarna Thangaraj, Munish Arora, Surjit Singh

{"title":"Treatment intensification in Kawasaki disease - current perspectives.","authors":"Prabal Barman, Rakesh Kumar Pilania, Gayathri Cv, Abarna Thangaraj, Munish Arora, Surjit Singh","doi":"10.1080/1744666X.2024.2378900","DOIUrl":"10.1080/1744666X.2024.2378900","url":null,"abstract":"Introduction: Intravenous immunoglobulin is the standard of care in Kawasaki disease. However, a subset of patients exhibits resistance to intravenous immunoglobulin treatment, even when Kawasaki disease is promptly diagnosed and managed. While intravenous immunoglobulin reduces the occurrence of coronary artery abnormalities from 15-25% to 3-5%, it does not entirely eliminate the risk. Besides, management guidelines for non-coronary complications of Kawasaki disease, for instance, myocarditis, remain speculative.Areas covered: Recent literature suggests that a subset of patients with Kawasaki disease may benefit from treatment intensification with drugs, such as corticosteroids, infliximab, anakinra, and/or ciclosporin. In this manuscript, we have reviewed recent advances in the management of Kawasaki disease, especially with regard to preemptive intensification of therapy in children at high risk of cardiac complications. A comprehensive search was made using Web of Science, Scopus, and PubMed databases to gather English articles published from 1967 to 2023 on the treatment of Kawasaki disease. We incorporated the following words in the search strategy: 'Kawasaki disease,' 'intravenous immunoglobulin/IVIg,' 'intravenous immunoglobulin/IVIg-resistant Kawasaki disease,' 'treatment intensification,' or 'primary intensification of treatment/therapy.'Expert opinion: The 'high-risk' group in Kawasaki disease needs to be identified with early intensification of primary therapy for better coronary and myocardial outcomes.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1179-1191"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of intense pulsed light combined with topical 0.05% Cyclosporin A eyedrops in the treatment of Sjögren's syndrome related dry eye. 强脉冲光与 0.05% 环孢素 a 外用眼药水联合治疗与斯约格伦综合征有关的干眼症的效果。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-05-27 DOI: 10.1080/1744666X.2024.2358157

Yanan Huo, Xiaodan Huang, Lin Lin, Shuo Yang, Zhenwei Qin, Zhu Yirui, Yujie Mou, Xiuming Jin

{"title":"The effect of intense pulsed light combined with topical 0.05% Cyclosporin A eyedrops in the treatment of Sjögren's syndrome related dry eye.","authors":"Yanan Huo, Xiaodan Huang, Lin Lin, Shuo Yang, Zhenwei Qin, Zhu Yirui, Yujie Mou, Xiuming Jin","doi":"10.1080/1744666X.2024.2358157","DOIUrl":"10.1080/1744666X.2024.2358157","url":null,"abstract":"Objectives: This study aimed to assess the effectiveness and safety of intense pulsed light (IPL) therapy plus topical 0.05% cyclosporine A (CsA) eye drops to treat Sjögren's Syndrome-related dry eyes (SS-DE).Research design and methods: In this prospective, randomized trial included, 60 individuals with SS-DE symptoms were randomized to receive topical eye drops containing either 0.1% sodium hyaluronate (Group S) or 0.05% CsA (Group C) plus IPL therapy. Before the first treatment (baseline), and at 12, 16, and 20 weeks after treatment commencement, we assessed the best corrected visual acuity (BCVA), the Ocular Surface Disease Index (OSDI) score, the Schirmer I test (SIT), noninvasive tear breakup time (NBUT), corneal fluorescein staining (CFS), meibomian gland (MG) dropout, lid margin abnormality, MG expressibility, and meibum quality.Results: Both groups showed significant improvements in the OSDI, NBUT, CFS, MG expressibility, and meibum quality (all p < 0.05). Group C showed a greater increase in OSDI, NBUT, MG expressibility, and meibum quality (all p < 0.05). Moreover, SIT and lid margin abnormalities significantly improved in Group C (both p < 0.05), but not in Group S.Conclusion: Treatment with 0.05% CsA eyedrops plus IPL therapy could significantly reduce the issues and physical discomfort of patients with SS-DE.Clinical trial: Registered on 20 July 2021, with the registration number ChiCTR2100049059.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1261-1267"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Salivary gland biopsy as a prognostic tool in Sjögren's syndrome. 唾液腺活检作为斯约格伦综合征的预后工具。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-06-24 DOI: 10.1080/1744666X.2024.2368189

Roberto Dal Pozzolo, Giacomo Cafaro, Carlo Perricone, Santina Calvacchi, Lorenza Bruno, Anna Colangelo, Francesco Tromby, Roberto Gerli, Elena Bartoloni

{"title":"Salivary gland biopsy as a prognostic tool in Sjögren's syndrome.","authors":"Roberto Dal Pozzolo, Giacomo Cafaro, Carlo Perricone, Santina Calvacchi, Lorenza Bruno, Anna Colangelo, Francesco Tromby, Roberto Gerli, Elena Bartoloni","doi":"10.1080/1744666X.2024.2368189","DOIUrl":"10.1080/1744666X.2024.2368189","url":null,"abstract":"Introduction: Primary Sjögren's syndrome (pSS) is an autoimmune disorder primarily affecting salivary and lacrimal glands, although about 40% of patients experience systemic complications. In this setting, the identification of patient phenotypes characterized by increased risk of extra-glandular involvement still represents an unmet need.Areas covered: The aim of this paper is to review the scientific evidence on the utility of salivary gland biopsies in pSS, emphasizing their role in defining prognosis. In latest years, research focused on disease-specific clinical, serological, or histological features able to categorize patient prognosis. Among histopathological features, focus score and ectopic germinal centers exhibit associations with glandular and extraglandular manifestations, including higher rates of lymphomagenesis.Expert opinion: Pathological characterization of salivary glands provides information that go beyond a mere diagnostic or classification utility, providing insights for a stratification of disease severity and for predicting systemic manifestations. Thus, a salivary gland biopsy should be offered to all patients and included in routine practice, even when not strictly required for diagnostic purposes. More advanced analysis techniques of the tissue, including immunohistochemistry and 'omics' should be further explored in longitudinal studies to boost the ability to further stratify and predict disease evolution.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1139-1147"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic accuracy of QuantiFERON-TB Gold Plus with Chemiluminescence Immunoassay: a systematic review and meta-analysis QuantiFERON-TB Gold Plus化学发光免疫测定的诊断准确性：系统综述和荟萃分析

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-19 DOI: 10.1080/1744666x.2024.2407550

Shima Mahmoudi, Seyed Mohammad Sajad Hosseini Sharif

引用次数: 0

Complement as a major mediator of ANCA vasculitis and a target for precision therapy 补体是 ANCA 血管炎的主要介质和精准治疗的靶点

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-18 DOI: 10.1080/1744666x.2024.2405170

Donna O. Bunch, Sarah E. Lewis, Hong Xiao, Peiqi Hu, J. Charles Jennette, Eveline Y. Wu

引用次数: 0

Innovative cell therapies for systemic sclerosis: available evidence and new perspectives 治疗系统性硬化症的创新细胞疗法：现有证据和新视角

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-16 DOI: 10.1080/1744666x.2024.2402494

Alain Lescoat, Monalisa Ghosh, Stephan Kadauke, Dinesh Khanna

引用次数: 0

Updating on pregnancy in rheumatoid arthritis. 类风湿关节炎患者怀孕的最新情况。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-05-20 DOI: 10.1080/1744666X.2024.2356164

Carlotta Schenone, Greta Pacini, Emanuele Gotelli, Elvis Hysa, Rosanna Campitiello, Silvia Sammorì, Sabrina Paolino, Alberto Sulli, Maurizio Cutolo

{"title":"Updating on pregnancy in rheumatoid arthritis.","authors":"Carlotta Schenone, Greta Pacini, Emanuele Gotelli, Elvis Hysa, Rosanna Campitiello, Silvia Sammorì, Sabrina Paolino, Alberto Sulli, Maurizio Cutolo","doi":"10.1080/1744666X.2024.2356164","DOIUrl":"10.1080/1744666X.2024.2356164","url":null,"abstract":"Introduction: Rheumatoid arthritis (RA), the most prevalent autoimmune disease in reproductive years, exhibits a higher incidence in females, suggesting involvement of estrogens, genetics and environmental factors in disease onset. Literature shows smaller families in RA patients, driving increased interest in Assisted Reproductive Techniques.Areas covered: This review elucidates how immunotolerance mechanisms contribute to favorable pregnancy outcomes in RA, emphasizing the need for a careful pregnancy planning to mitigate fetal complications and postnatal flares, which surpass those in the general population. A thorough medication evaluation, orchestrated by a multidisciplinary team, is imperative during pregnancy, weighing potential teratogenic effects against safer alternatives to balance medication safety with disease control. A systematic literature search on PubMed and MEDLINE, using specific terms, covered relevant academic journals up to the latest date.Expert opinion: This narrative review comprehensively addresses pregnancy-related considerations in RA patients, prioritizing meticulous disease management with pregnancy and breastfeeding-compatible drugs in line with the latest recommendations and registry data. The focus remains on evaluating glucocorticoids, conventional, and biological disease-modifying drugs for compatibility during pregnancy and breastfeeding. Additionally, the evolving landscape of targeted synthetic drugs during pregnancy is explored, providing insights into the latest developments in rheumatological care.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1041-1052"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can we define difficult-to-treat systemic sclerosis? 我们能否定义难以治疗的系统性硬化症？

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-05-14 DOI: 10.1080/1744666X.2024.2352450

Gabriella Szűcs, Zoltán Szekanecz, Szilvia Szamosi

{"title":"Can we define difficult-to-treat systemic sclerosis?","authors":"Gabriella Szűcs, Zoltán Szekanecz, Szilvia Szamosi","doi":"10.1080/1744666X.2024.2352450","DOIUrl":"10.1080/1744666X.2024.2352450","url":null,"abstract":"Introduction: Systemic sclerosis (SSc) is a chronic autoimmune rheumatic disease characterized by microvascular alterations, immunopathology, and widespread fibrosis involving various organs. It is considered difficult to treat due to several reasons: complex pathogenesis, heterogeneity, late diagnosis, limited treatment options for certain organ manifestations, lack of personalized medicine.Areas covered: This review presents the heterogeneity, survival and organ manifestations with their risk factors of systemic sclerosis and their current treatment options, while drawing attention to difficult-to-treat forms of the disease, based on literature indexed in PubMed.Expert opinion: Despite recent advances in the management of SSc over the last decades, the disease presents significant morbidity and mortality. Although available treatment protocols brought significant advancements in terms of survival in SSc-associated interstitial lung disease and pulmonary arterial hypertension, less success has been achieved in the treatment of Raynaud's phenomenon and digital ulcers and the results are modest in case of heart, gastrointestinal, and renal manifestations. There are patients who do not respond to treatment and deteriorate even with adequate therapy. They can be considered difficult-to treat (D2T) cases. We have created a possible score system based on the individual organ manifestations and highlighted treatment options for the D2T SSc category.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1065-1081"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atopic dermatitis stratification: current and future perspective on skin and blood transcriptomic and proteomic profiling. 特应性皮炎分层：皮肤和血液转录组学与蛋白质组学分析的现状与未来展望。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-03-04 DOI: 10.1080/1744666X.2024.2323964

Kelly Hawkins, Eden David, Jacob W Glickman, Ester Del Duca, Emma Guttman-Yassky, James G Krueger

{"title":"Atopic dermatitis stratification: current and future perspective on skin and blood transcriptomic and proteomic profiling.","authors":"Kelly Hawkins, Eden David, Jacob W Glickman, Ester Del Duca, Emma Guttman-Yassky, James G Krueger","doi":"10.1080/1744666X.2024.2323964","DOIUrl":"10.1080/1744666X.2024.2323964","url":null,"abstract":"Introduction: Atopic dermatitis (AD) is a common, chronic inflammatory skin disorder driven by an intricate interplay of genetic, environmental, and immunological factors.Areas covered: As a clinically heterogenous condition, AD may be stratified into subtypes based on factors including, chronicity, immunoglobulin E levels, severity, age, and ethnicity. Transcriptomic and proteomic analyses in skin and blood help elucidate the underlying molecular mechanisms of these AD subtypes, referred to as AD endotypes. Further characterizing AD endotypes using reliable biomarkers can facilitate the development of more effective and personalized therapeutics and improve our tools for monitoring disease progression and therapeutic response across a diverse subset of patients. Here, we aim to provide perspective on the latest research regarding AD stratification using skin and blood-based studies and insight into the implications of these findings on the future of AD research and clinical practice.Expert opinion: The precise stratification of AD endotypes will allow for the development of reliable biomarkers and a more personalized medical treatment approach. Clinical practice and trials will eventually be able to bridge clinical with molecular data to optimize individualized treatments and more effectively monitor treatment response.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1083-1088"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140021288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunology and targeted therapy in Castleman disease. 卡斯特曼病的免疫学和靶向治疗。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-05-27 DOI: 10.1080/1744666X.2024.2357689

Shinichiro Tsunoda, Takuya Harada, Yoshikane Kikushige, Tadamitsu Kishimoto, Kazuyuki Yoshizaki

{"title":"Immunology and targeted therapy in Castleman disease.","authors":"Shinichiro Tsunoda, Takuya Harada, Yoshikane Kikushige, Tadamitsu Kishimoto, Kazuyuki Yoshizaki","doi":"10.1080/1744666X.2024.2357689","DOIUrl":"10.1080/1744666X.2024.2357689","url":null,"abstract":"Introduction: Castleman disease (CD) is a benign lymphoproliferative disease causing severe systemic inflammation. Interleukin-6 (IL-6) is a major pathogenesis of multicentric CD (MCD), but only 30-60% of patients respond to IL-6 inhibitors. Novel agents for IL-6 inhibitor-refractory cases are needed. Clinical data and samples are being collected on a large scale and the clinical, pathological, and pathogenetic aspects are being elucidated.Areas covered: The pathological and clinical classification of CD is outlined. Focusing on idiopathic MCD (iMCD), this review identifies therapeutic targets and summarizes currently recommended drugs and promising therapeutic candidates.Expert opinion: The pathogenesis of MCD has been implicated in the activation of the Janus kinase (JAK)-transcriptional signaling activator (STAT) 3 pathway and the phosphatidylinositol 3-kinase (PI3K)/Akt/mechanical target of rapamycin (mTOR) signaling pathway. iMCD-TAFRO (thrombocytopenia, anasarca, fever/elevated CRP, reticulin myelofibrosis/renal dysfunction, organ enlargement) is resistant to IL-6 inhibitors, and cyclosporine and mTOR inhibitors are sometimes effective. JAK inhibitors and mTOR inhibitors may be therapeutic agents for iMCD. Recently, we have shown that peripheral helper T (Tph) cell abnormalities are at the core of iMCD pathogenesis. Therapies targeting chemokine (C-X-C motif) ligand 13 (CXCL13) produced by Tph cells and blocking the Tph-CXCL13-B cell pathway may satisfy unmet need in refractory cases.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1101-1112"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0